Oral delivery of poorly water-soluble drugs
D4 is internationally recognised for its expertise in designing delivery systems to optimise the bioavailability of poorly water-soluble drugs after oral administration. In recent years, the number of drug candidates with very low water solubility has increased significantly. Highly lipophilic, poorly water-soluble drug molecules are often highly potent. However, low water solubility typically limits drug absorption after oral administration, ultimately limiting clinical usefulness.
D4 researchers in this area have particular expertise in the formulation and evaluation of lipid-based delivery systems, and have pioneered the use of in vitro lipolysis tests to optimise the design of these systems. A complementary interest is the design of polymers that act as precipitation inhibitors, reducing the extent of precipitation of drugs during dispersion and digestion. Our research is also investigating the formulation of electrolytes as ionic liquids, which can increase the mass of drug that can be administered in each capsule.
These research programs are well supported by Australian Research Council, the National Health and Medical Research Council and the pharmaceutical industry.